XTX Topco Ltd purchased a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,495 shares of the company's stock, valued at approximately $332,000.
Other hedge funds also recently modified their holdings of the company. Deutsche Bank AG lifted its holdings in shares of MoonLake Immunotherapeutics by 59.8% during the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after purchasing an additional 338 shares during the period. Birchview Capital LP acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth $217,000. Legato Capital Management LLC acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth $240,000. PEAK6 LLC acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth $271,000. Finally, Mariner LLC acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth $272,000. Institutional investors and hedge funds own 93.85% of the company's stock.
MoonLake Immunotherapeutics Trading Up 1.0%
MLTX opened at $52.40 on Friday. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The company has a current ratio of 16.65, a quick ratio of 21.11 and a debt-to-equity ratio of 0.21. The company has a market cap of $3.35 billion, a P/E ratio of -18.85 and a beta of 1.27. The company has a fifty day moving average price of $48.87 and a two-hundred day moving average price of $43.14.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the previous year, the company earned ($0.39) EPS. Analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently commented on MLTX shares. Rothschild & Co Redburn started coverage on shares of MoonLake Immunotherapeutics in a report on Monday, July 28th. They set a "neutral" rating and a $65.00 price target on the stock. The Goldman Sachs Group boosted their target price on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a report on Wednesday. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price on the stock in a report on Monday, May 19th. Royal Bank Of Canada restated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Finally, Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $74.43.
View Our Latest Research Report on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Company Profile
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Articles
Want to see what other hedge funds are holding MLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.